Edesa Biotech, headquartered in Markham, Ontario, focuses on developing clinical-stage drugs for inflammatory diseases, including EB05 for ARDS and EB01 for chronic allergic dermatitis. The company employs 16 staff and went public in 2008.
Edesa Biotech (EDSA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Edesa Biotech's actual EPS was -$0.48, missing the estimate of -$0.32 per share, resulting in a -51.80% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
